Clinical trial · Interventional
Paclitaxel in Treating Patients With Lung Cancer
Phase II Study on TAXOL in Bronchioalveolar Carcinoma
NCT00002972CI-TRIAL-00007326completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have unresectable stage IIIB, stage IV or recurrent lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| paclitaxel | Drug | Paclitaxel | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven bronchoalveolar carcinoma (BAC) based on these criteria: * Absence of primary adenocarcinoma elsewhere * Absence of a demonstrable central bronchogenic origin * A peripheral location in the lung parenchyma * Intact interstitial framework of the lung * A histological appearance setting it apart from other tumors, with a characteristic pattern of growth: cuboidal or cylindrical cells lining up the alveolar septa with preservation of basic pulmonary architecture * Must be unresectable Stage IIIB, IV, or recurrent BAC * Evidence of multinodular lesions involving the lungs bilaterally or unilaterally (in the latter the lesions must involve more than one lobe) * At least one target lesion bidimensionally measurable that has not undergone prior irradiation * No CNS disease PATIENT CHARACTERISTICS: Age: * 18 to 75 (inclusive) Performance status: * ECOG 0-2 Life expectancy: * Greater than 3 months Hematopoietic: * ANC at least 1,500/mm\^3 Hepatic: * Bilirubin less than 2 times upper limit of normal * SGOT, SGPT, and alkaline phosphatase less than 2 times upper limit of normal Renal: * Creatinine less than 1.5 times upper limit of normal Cardiovascular: * No history of ischemic or congestive heart disease * No arrhythmia requiring chronic cardiopulmonary medications * No history of clinically or electrographically documented myocardial infarction Other: * No preexisting motor or other serious sensory neurotoxicity * No active or prior second primary cancer except basal cell carcinoma of the skin or carcinoma in situ of the cervix * No clinical evidence of uncontrolled infection * Not pregnant or nursing * Negative pregnancy test 72 hours prior to start of study medication * Adequate contraception required of all fertile patients PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 4 weeks since radiotherapy * Must have at least one bidimensional lesion outside the irradiated fields Surgery: * Fully recovered from any prior major surgery
References
Publications (1)
- RESULTScagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid-Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer. 2005 Oct;50(1):91-6. doi: 10.1016/j.lungcan.2005.05.012. PMID 16019107